{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(1)"],"submitter":["Tran B"],"pubmed_abstract":["<h4>Background</h4>Metastatic germ cell tumor (mGCT) patients receiving chemotherapy have increased risk of life-threatening venous thromboembolism (VTE). Identifying VTE risk factors may guide thromboprophylaxis in this highly curable population.<h4>Methods</h4>Data were collected from mGCT patients receiving first-line platinum-based chemotherapy at 22 centers. Predefined variables included International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification, long-axis diameter of largest retroperitoneal lymph node (RPLN), Khorana score, and use of indwelling vascular access device (VAD). VTE occurring at baseline, during chemotherapy and within 90 days, was analyzed.<h4>Results</h4>Data from 1135 patients were collected. Median age was 31 years (range 10-74). IGCCCG risk was "],"journal":["Cancer medicine"],"pagination":["116-124"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6943085"],"repository":["biostudies-literature"],"pubmed_title":["Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)."],"pmcid":["PMC6943085"],"pubmed_authors":["Gonzalez-Billalabeitia E","Brito M","Hermanns T","Kwan EM","Reid A","Seidel C","Tran B","Amir E","Ruiz-Morales JM","Tryakin A","Flechon A","Rumyantsev A","Bedard PL","Ottaviano M","Kitson R","Cheng T","Bokemeyer C","Castellano D","Palmieri G","Patrikidou A","Hamid AA","Fankhauser C","Garcia Del Muro X","Heng DYC"],"additional_accession":[]},"is_claimable":false,"name":"Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3).","description":"<h4>Background</h4>Metastatic germ cell tumor (mGCT) patients receiving chemotherapy have increased risk of life-threatening venous thromboembolism (VTE). Identifying VTE risk factors may guide thromboprophylaxis in this highly curable population.<h4>Methods</h4>Data were collected from mGCT patients receiving first-line platinum-based chemotherapy at 22 centers. Predefined variables included International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification, long-axis diameter of largest retroperitoneal lymph node (RPLN), Khorana score, and use of indwelling vascular access device (VAD). VTE occurring at baseline, during chemotherapy and within 90 days, was analyzed.<h4>Results</h4>Data from 1135 patients were collected. Median age was 31 years (range 10-74). IGCCCG risk was ","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jan","modification":"2025-05-29T21:27:13.029Z","creation":"2025-05-29T21:27:13.029Z"},"accession":"S-EPMC6943085","cross_references":{"pubmed":["31715650"],"doi":["10.1002/cam4.2674"]}}